MIST SEC Filings - Milestone Pharmaceuticals Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

1408443

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Milestone Pharmaceuticals Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

August 12, 2025	EX-FILING FEES	Filing Fee Table Calculation of Filing Fee Tables S-8 Milestone Pharmaceuticals Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2019 Equity Incentive Plan (Common shares, no par value per share) Other 4,000,000 $ 1.51 $ 6,040,000.
August 12, 2025	S-8	As filed with the Securities and Exchange Commission on August 12, 2025 As filed with the Securities and Exchange Commission on August 12, 2025 Registration No.
August 12, 2025	EX-99.1	Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Mil Exhibit 99.1 Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved Public Offering Raised Total Gross Proceeds of up to $170 M
August 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 MILESTONE PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (C
August 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc.
July 14, 2025	EX-1.1	Underwriting Agreement, dated July 11, 2025, by and among the Company, TD Securities (USA) LLC, Piper Sandler & Co. and Wells Fargo Securities, LLC Exhibit 1.1 EXECUTION VERSION Milestone Pharmaceuticals Inc. 31,500,000 Common Shares Pre-Funded Warrants to Purchase 3,502,335 Common Shares Series A Warrants to Purchase 35,002,335 Common Shares Series B Warrants to Purchase 35,002,335 Common Shares UNDERWRITING AGREEMENT July 11, 2025 TD Securities (USA) LLC Piper Sandler & Co. Wells Fargo Securities, LLC As Representatives of the several Under
July 14, 2025	EX-4.2	Form of Series A Common Warrant Exhibit 4.2 Milestone Pharmaceuticals Inc. FORM OF SERIES A COMMON WARRANT TO PURCHASE COMMON SHARES Number of Shares: [●] (subject to adjustment) Warrant No. A - [●] Original Issue Date: July 14, 2025 Milestone Pharmaceuticals Inc., an exempted company incorporated and existing under the laws of the Province of Québec, Canada (the “Company”), hereby certifies that, for good and valuable considera
July 14, 2025	EX-99.1	Milestone Pharmaceuticals Announces Proposed Public Offering Exhibit 99.1 Milestone Pharmaceuticals Announces Proposed Public Offering MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) - Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares, accompanying Series A warrants to purchase common shares (the “Series A Warrants”) an
July 14, 2025	EX-99.2	Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants Exhibit 99.2 Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) - Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative c
July 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 MILESTONE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Com
July 14, 2025	EX-4.1	Form of Pre-Funded Warrant Exhibit 4.1   Milestone Pharmaceuticals Inc. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES   Number of Shares: [●] (subject to adjustment)   Warrant No. PFW2025 - [●]   Original Issue Date: July 14, 2025       Milestone Pharmaceuticals Inc., an exempted company incorporated and existing under the laws of the Province of Québec, Canada (the “Company”), hereby certifies that, for good and val
July 14, 2025	EX-4.3	Form of Series B Common Warrant Exhibit 4.3 Milestone Pharmaceuticals Inc. FORM OF SERIES B COMMON WARRANT TO PURCHASE COMMON SHARES Number of Shares: [●] (subject to adjustment) Warrant No. B - [●] Original Issue Date: July 14, 2025 Milestone Pharmaceuticals Inc., an exempted company incorporated and existing under the laws of the Province of Québec, Canada (the “Company”), hereby certifies that, for good and valuable considera
July 14, 2025	424B5	31,500,000 Common Shares Pre-Funded Warrants to Purchase 3,502,335 Common Shares Series A Common Warrants to Purchase 35,002,335 Common Shares Series B Common Warrants to Purchase 35,002,335 Common Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-283162 PROSPECTUS SUPPLEMENT(To Prospectus Dated November 12, 2024) 31,500,000 Common Shares Pre-Funded Warrants to Purchase 3,502,335 Common Shares Series A Common Warrants to Purchase 35,002,335 Common Shares Series B Common Warrants to Purchase 35,002,335 Common Shares We are offering an aggregate of 31,500,000 common s
July 11, 2025	EX-99.1	Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 Exhibit 99.1 Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 Montreal and Charlotte, N.C., July 11, 2025 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food
July 11, 2025	424B5	Common Shares Pre-Funded Warrants to Purchase Common Shares Series A Common Warrants to Purchase Common Shares Series B Common Warrants to Purchase Common Shares TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.
July 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 MILESTONE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Com
June 16, 2025	EX-99.1	Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting Exhibit 99.1 Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting Montreal and Charlotte, N.C., June 16, 2025 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug Application (NDA
June 16, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 MILESTONE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Com
June 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 MILESTONE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Com
June 12, 2025	EX-10.1	2019 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on June 12, 2025). Exhibit 10.1 MILESTONE PHARMACEUTICALS INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 10, 2019 APPROVED BY THE SHAREHOLDERS: APRIL 29, 2019 IPO DATE: MAY 8, 2019 AMENDED BY THE BOARD OF DIRECTORS: APRIL 19, 2022 APPROVED BY THE SHAREHOLDERS: JULY 5, 2022 AMENDED BY THE BOARD OF DIRECTORS: APRIL 30, 2025 APPROVED BY THE SHAREHOLDERS: JUNE 10, 2025 1.             GENERAL. (
May 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 MILESTONE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Comm
May 14, 2025	EX-99.1	Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA Exhibit 99.1 Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) - Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial result
May 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc.
April 30, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
April 30, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
March 28, 2025	EX-99.1	FDA Issues Complete Response Letter for Etripamil for PSVT CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 Exhibit 99.1 FDA Issues Complete Response Letter for Etripamil for PSVT CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issue
March 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 MILESTONE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 19, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 MILESTONE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 MILESTONE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 18, 2025	424B5	Up to $75,000,000 Common Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-283162 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 22, 2024) Up to $75,000,000 Common Shares We have entered into an Amended and Restated Open Market Sale AgreementSM, or the sale agreement, with Jefferies LLC, or Jefferies, dated March 18, 2025, relating to the sale of our common shares offered by this prospectus su
March 18, 2025	EX-1.1	Amended and Restated Open Market Sale AgreementSM, dated March 18, 2025, by and between Milestone Pharmaceuticals Inc. and Jefferies LLC. Exhibit 1.1 AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSM March 18, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Milestone Pharmaceuticals Inc., a corporation continued under the laws of the Province of Québec, Canada (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as
March 13, 2025	S-8	As filed with the Securities and Exchange Commission on March 13, 2025 As filed with the Securities and Exchange Commission on March 13, 2025 Registration No.
March 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 13, 2025	EX-19.1	Insider Trading Policy. Exhibit 19.1 Milestone Pharmaceuticals Inc. Insider Trading Policy I. Introduction During the course of your employment, directorship or consultancy with Milestone Pharmaceuticals Inc. (the “Company”), you may receive important information that is not yet publicly available (“inside information”) about the Company or about other publicly traded companies with which the Company has business dealing
March 13, 2025	EX-4.5	Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Milestone Pharmaceuticals Inc. (the “Company”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our securit
March 13, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Milestone Pharmaceuticals, Inc.
March 13, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-388
March 13, 2025	EX-99.1	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tac Exhibit 99.1 Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for mid-2025 Milestone well-capitalized to commercialize upon app
February 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 MILESTONE PHARM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation)
February 25, 2025	EX-99.1	Commercial Investor Event: Preparation for Potential Launch of CARDAMYST (etripamil) Nasal Spray Joe Oliveto, President & CEO Lorenz Muller, CCO Investigational Product. Not approved for commercial use in any jurisdiction. Disclaimer This presentatio Exhibit 99.1 Commercial Investor Event: Preparation for Potential Launch of CARDAMYST (etripamil) Nasal Spray Joe Oliveto, President & CEO Lorenz Muller, CCO Investigational Product. Not approved for commercial use in any jurisdiction. Disclaimer This presentation discusses our intended promotional launch strategy for CARDAMYSTTM (etripamil) nasal spray, which has not yet been approved for commerc
November 20, 2024	CORRESP	Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 420 Montréal, Québec CA H4M 2X6 Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 420 Montréal, Québec CA H4M 2X6 VIA EDGAR November 20, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards Re: Milestone Pharmaceuticals Inc. Registration Statement on Form S-3 File No. 333-283162 Acceleration Request Requested Date: Frida
November 12, 2024	EX-99.1	Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 Exhibit 99.1 Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided
November 12, 2024	S-8	As filed with the Securities and Exchange Commission on November 12, 2024 As filed with the Securities and Exchange Commission on November 12, 2024 Registration No.
November 12, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Milestone Pharmaceuticals Inc.
November 12, 2024	S-3	As filed with the Securities and Exchange Commission on November 12, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 12, 2024 Registration No.
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc.
November 12, 2024	EX-10.1	Non-Employee Director Compensation Policy, as amended (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38899), filed with the SEC on November 12, 2024). Exhibit 10.1 MILESTONE PHARMACEUTICALS INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of Milestone Pharmaceuticals Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Direct
November 12, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation)
November 12, 2024	EX-4.5	Form of Common Share Warrant Agreement and Warrant Certificate. Exhibit 4.5 Milestone Pharmaceuticals Inc. and , As Warrant Agent Form of Common Share Warrant Agreement Dated As Of Milestone Pharmaceuticals Inc. Form of Common Share Warrant Agreement This Common Share Warrant Agreement (this “Agreement”), dated as of [●], between MILESTONE PHARMACEUTICALS INC., a corporation existing under the laws of the province of Québec (the “Company”), and [●], a [corpora
November 12, 2024	EX-4.3	Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.3 Milestone Pharmaceuticals Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificat
November 12, 2024	EX-4.6	Form of Preferred Share Warrant Agreement and Warrant Certificate. Exhibit 4.6 Milestone Pharmaceuticals Inc. and , As Warrant Agent Form of Preferred Share Warrant Agreement Dated As Of Milestone Pharmaceuticals Inc. Form of Preferred Share Warrant Agreement This Preferred Share Warrant Agreement (this “Agreement”), dated as of [●], between Milestone Pharmaceuticals Inc., a corporation existing under the laws of the province of Québec (the “Company”), and [●], a
November 12, 2024	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.7 Milestone Pharmaceuticals Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Milestone Pharmaceuticals Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Milestone Pharmaceuticals Inc., a corporation organized under the laws of the province of Québec (the “Company”), and [●],
November 12, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Milestone Pharmaceuticals, Inc.
October 29, 2024	SC 13G/A	MIST / Milestone Pharmaceuticals Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 3) MILESTONE PHARMACEUTICALS INC. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 59935V107 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule
September 4, 2024	EX-99.1	Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors Exhibit 99.1 Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors MONTREAL and CHARLOTTE, N.C., September 4, 2024 (GLOBE NEWSWIRE) - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Di
September 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 MILESTONE PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (C
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc.
August 8, 2024	EX-99.1	Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update – NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as of June 30, 2024 expected to Exhibit 99.1 Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update – NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 – Stuart Duty and Andrew Saik Appointed as Independent Board Directors MONTREAL and CHARLOTTE, N.C., August 8,
August 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 MILESTONE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
July 16, 2024	SC 13D/A	MIST / Milestone Pharmaceuticals Inc. / Alta Fundamental Advisers LLC - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 59935V107 (CUSIP Number) Gilbert Li Alta Fun
July 15, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
July 15, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
July 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2024 MILESTONE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Com
July 15, 2024	EX-10.1	Cooperation Agreement, dated as of July 14, 2024, by and between the Company and Alta Fundamental Advisers Master L.P. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on July 15, 2024). Exhibit 10.1 Execution Version COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”) is made and entered into as of July 14, 2024 (the “Effective Date”), by and between Milestone Pharmaceuticals Inc. (the “Company”) and Alta Fundamental Advisers LLC (“Alta”). The Company and Alta are each herein referred to as a “party” and collectively, the “parties.” Capitalized terms used herein a
July 15, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2024 MILESTONE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Com
July 15, 2024	EX-99.1	– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term Exhibit 99.1 Milestone Pharmaceuticals Refreshes Board of Directors – Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C. – July 15, 2024 – Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (“Milestone” or the “Company”), a biopharmaceutical company focused on the development and comm
May 29, 2024	EX-99.1	Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™ Exhibit 99.1 Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™ Montreal and Charlotte, N.C., May, 29, 2024 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the United States Food and Drug Administration (FDA) accepted the
May 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 MILESTONE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Comm
May 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 MILESTONE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Comm
May 13, 2024	EX-10.1	Non-Employee Director Compensation Policy, as amended. Exhibit 10.1 MILESTONE PHARMACEUTICALS INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of Milestone Pharmaceuticals Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Direct
May 13, 2024	EX-99.1	Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - NDA for etripamil in PSVT resubmitted in 1Q 2024 - Cash resources as of March 31, 2024 expected to fund operations into 2026 - Dialo Exhibit 99.1 Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - NDA for etripamil in PSVT resubmitted in 1Q 2024 - Cash resources as of March 31, 2024 expected to fund operations into 2026 - Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR is progressing MONTREAL and CHARLOTTE, N.C., May 13, 2024 (GLOBE NEWS
May 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc.
April 29, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ¨ TRAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-3
April 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 MILESTONE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Com
April 8, 2024	EX-99.1	Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting Data from this large safety-trial also published in The Journal of the A Exhibit 99.1 Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting Data from this large safety-trial also published in The Journal of the American College of Cardiology Montreal and Charlotte, N.C., April 8, 2024 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceu
March 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 MILESTONE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 28, 2024	EX-99.1	Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia Exhibit 99.1 Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia Montreal and Charlotte, N.C., March 28, 2024 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the resubmissio
March 21, 2024	EX-97.1	Incentive Compensation Recoupment Policy (incorporated herein by reference to Exhibit 97.1 to the Registrant’s Annual Report on Form 10-K (File No. 001-38899), filed with the SEC on March 21, 2024). Exhibit 97.1 MILESTONE PHARMACEUTICALS INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1.INTRODUCTION The Board of Directors (the “Board”) of Milestone Pharmaceuticals Inc., a corporation existing under the Business Corporations Act (Québec) (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensation Recoupment Policy (thi
March 21, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-388
March 21, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 21, 2024	EX-99.1	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update - On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA r Exhibit 99.1 Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update - On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting expected mid-2024 MONTREAL and CHARLOTTE, N.C., March
March 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 MILESTONE PHARM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation)
March 4, 2024	EX-4.1	Form of Pre-Funded Warrant Exhibit 4.1 UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [●], 20[●]. Milestone Pharmaceuticals Inc. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Number of Shares: [●] (subject to adjustment) Warrant No. PFW2024 - [●] Original Issue Date: [●], 20[●] Milestone Pharmaceuticals Inc., an exempted company incorporated and existing
March 4, 2024	EX-99.1	Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants Exhibit 99.1 Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants MONTREAL, QC and CHARLOTTE, N.C., February 28, 2023 /PRNewswire/ - Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has commenced a
March 4, 2024	EX-1.1	Underwriting Agreement, dated February 28, 2024, by and between the Company and Piper Sandler & Co. Exhibit 1.1 Milestone Pharmaceuticals Inc. 16,666,667 Common Shares Pre-Funded Warrants to Purchase 3,333,333 Common Shares UNDERWRITING AGREEMENT February 28, 2024 Piper Sandler & Co. As Representative of the several Underwriters c/o Piper Sandler & Co. 1251 Avenue of the Americas, 7th Floor New York, New York 10020 Dear Sirs: 1.             Introductory. Milestone Pharmaceuticals Inc., a corpora
March 4, 2024	EX-99.2	Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants Exhibit 99.2 Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants MONTREAL, QC and CHARLOTTE, N.C., February 29, 2024 /PRNewswire/ - Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pri
March 1, 2024	424B5	16,666,667 Common Shares Pre-Funded Warrants to Purchase 3,333,333 Common Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-261049 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 2, 2022) 16,666,667 Common Shares Pre-Funded Warrants to Purchase 3,333,333 Common Shares We are offering 16,666,667 common shares pursuant to this prospectus supplement. We are also offering to certain investors the opportunity to purchase, in lieu of common shares,
February 28, 2024	424B5	SUBJECT TO COMPLETION, DATED FEBRUARY 28, 2024 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.
February 26, 2024	EX-99.1	Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT Resubmission of NDA expected 2Q2024 Operating Runway Extended Into Mid-2025 with Cash Conservation Measures Exhibit 99.1 Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT Resubmission of NDA expected 2Q2024 Operating Runway Extended Into Mid-2025 with Cash Conservation Measures Montreal, QC and Charlotte, N.C., February 26, 2024 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced plans to resubmit the New Drug Application (NDA) for etripamil to
February 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 MILESTONE PHARM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation)
February 14, 2024	SC 13G/A	MIST / Milestone Pharmaceuticals Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate th
February 14, 2024	SC 13G/A	MIST / Milestone Pharmaceuticals Inc. / RTW INVESTMENTS, LP - MILESTONE PHARMACEUTICALS INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pu
January 29, 2024	SC 13G/A	MIST / Milestone Pharmaceuticals Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) MILESTONE PHARMACEUTICALS INC. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 59935V107 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule p
December 26, 2023	EX-99.1	Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT Exhibit 99.1 Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT Montreal and Charlotte, N.C., December 26, 2023 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) announced today that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (ND
December 26, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation)
November 13, 2023	EX-10.1	First Amendment to Note Purchase Agreement, dated as of August 4, 2023 (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38899), filed with the SEC on November 13, 2023). Exhibit 10.1 Execution Version FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT This FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT, dated as of August 4, 2023 (“Amendment”), is made by and among Milestone Pharmaceuticals Inc., a corporation existing under the Business Corporations Act (Québec) (the “Company”), the Purchasers (defined below), RTW Investments, LP, as agent for the Purchasers (in such capacit
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2023 MILESTONE PHARM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation)
November 13, 2023	EX-99.1	Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates Exhibit 99.1 Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates - New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, for patients with PSVT - Positive Phase 2 data evaluating etripamil in AFib-RVR were a Featured Science Presentation
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc.
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 MILESTONE PHARM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation)
November 13, 2023	EX-99.1	Company Overview CONFIDENTIAL Atrial Fibrillation Program Update November 2023 Exhibit 99.1 Company Overview CONFIDENTIAL Atrial Fibrillation Program Update November 2023 Forward Looking Statement 2 Milestone - Atrial Fibrillation Program Overview The Presentation contains forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words such as ‘‘aim,’’ ‘‘anticipate,’’ ‘‘assume,’’ ‘‘belie
November 13, 2023	EX-99.2	Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 Exhibit 99.2 Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 · Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p < 0.0001) compared to placebo · Re
November 13, 2023	EX-10.2	Non-Employee Director Compensation Policy, as amended (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38899), filed with the SEC on November 13, 2023). Exhibit 10.2 MILESTONE PHARMACEUTICALS INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of Milestone Pharmaceuticals Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Direct
November 9, 2023	SC 13D	MIST / Milestone Pharmaceuticals Inc / Alta Fundamental Advisers LLC - THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 59935V107 (CUSIP Number) Gilbert Li Alta Fund
November 9, 2023	EX-99.2	JOINT FILING AGREEMENT EX-99.2 3 ex992to13d1220800311092023.htm JOINT FILING AGREEMENT Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Shares, no par value, of Mil
November 9, 2023	EX-99.1	November 9, 2023 EX-99.1 2 ex991to13d1220800311092023.htm LETTER TO THE BOARD, DATED NOVEMBER 9, 2023 Exhibit 99.1 November 9, 2023 Milestone Pharmaceuticals 1111 Dr. Frederik-Philips Boulevard, Suite 420 Montreal, Quebec CA H4M 2x6 Attention: Board of Directors Dear Members of the Board, By way of re-introduction, our firm – a New York based private investment fund – seeks to invest in undervalued companies that
November 7, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (
November 7, 2023	EX-99.1	Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR - Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm, MD, and Sean Pokorney, MD - Con Exhibit 99.1 Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR - Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm, MD, and Sean Pokorney, MD - Conference call and webcast on Monday, November 13, 2023 at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., Nov. 7, 2023 /PRNewswire/ - Milestone
October 24, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (
October 24, 2023	EX-99.1	Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil Exhibit 99.1 Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil · Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVT · Comprehensive data package includes positive results from pivotal Phase 3 RAPID trial which Company believes demonstrates new calcium channel blocker, etripamil, is
August 10, 2023	EX-99.1	Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update - NDA submission for etripamil in patients with PSVT expected in October 2023 - Data featured during oral session at Heart Rhythm 2023 Exhibit 99.1 Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update - NDA submission for etripamil in patients with PSVT expected in October 2023 - Data featured during oral session at Heart Rhythm 2023 Annual Meeting support the potential of etripamil in patients with AFib-RVR - Enrollment complete in Phase 2 ReVeRA study of etripamil in
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc.
August 10, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (C
June 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 MILESTONE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Comm
May 31, 2023	424B5	Up to $47,249,368 Common Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-261049 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 12, 2021) Up to $47,249,368 Common Shares This prospectus supplement amends and restates the information in our prospectus supplement dated July 29, 2020 and, accordingly, the information in this prospectus supplement supersedes the information contained in that pr
May 31, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ¨ TRAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-3
May 24, 2023	CORRESP	Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 420 Montréal, Québec CA H4M 2X6 Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 420 Montréal, Québec CA H4M 2X6 VIA EDGAR May 24, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jason Drory Re: Milestone Pharmaceuticals Inc. Registration Statement on Form S-3, as amended File No. 333-271949 Acceleration Request Requested Date:
May 15, 2023	EX-FILING FEES	Filing fee table. EXHIBIT 107 Calculation of Filing Fee Table Form S-3 (Form Type) Milestone Pharmaceuticals Inc.
May 15, 2023	S-3	As filed with the Securities and Exchange Commission on May 15, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 15, 2023 Registration No.
May 15, 2023	EX-4.3	Form of Note. Exhibit 4.3 FORM OF NOTE [FORM OF FACE OF NOTE] THIS NOTE AND THE COMMON SHARES, IF ANY, ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND ACCORDINGLY, PRIOR TO THE RESALE RESTRICTION TERMINATION DATE (AS DEFINED BELOW), MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLL
May 11, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Comm
May 11, 2023	EX-99.1	Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update - NDA submission for etripamil in patients with PSVT currently on track for 3Q23 - Company to host virtual KOL event focused on etripami Exhibit 99.1 Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update - NDA submission for etripamil in patients with PSVT currently on track for 3Q23 - Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on Monday, May 22, 2023 - Topline data from Phase 2 ReVeRA study evaluating etripamil in patien
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc.
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
April 28, 2023	S-8	As filed with the Securities and Exchange Commission on April 28, 2023 As filed with the Securities and Exchange Commission on April 28, 2023 Registration No.
April 28, 2023	DEF 14A	Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 28, 2023; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
April 28, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Milestone Pharmaceuticals, Inc.
March 31, 2023	8-K	Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 31, 2023	EX-10.2	Note Purchase Agreement, dated as of March 27, 2023, by and among the Company and RTW (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on March 31, 2023). Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MILESTONE PHARMACEUTICALS INC. TREATS AS PRIVATE OR CONFIDENTIAL NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”) is entered into as of March 27, 2023 (the “Execution Date”) by and among Milestone Pharmaceut
March 31, 2023	EX-99.1	Company Overview March 30, 2023 Exhibit 99.1 Company Overview March 30, 2023 Forward Looking Statement 2 Milestone Corporate Overview The Presentation contains forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words such as ‘‘aim,’’ ‘‘anticipate,’’ ‘‘assume,’’ ‘‘believe,’’ ‘‘contemplate,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘design,’’ ‘‘due,’
March 31, 2023	EX-10.1	Royalty Purchase Agreement, dated as of March 27, 2023, by and among the Company and RTW (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on March 31, 2023). Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MILESTONE PHARMACEUTICALS INC. TREATS AS PRIVATE OR CONFIDENTIAL Purchase and Sale Agreement By and Between Milestone Pharmaceuticals Inc. and RTW Royalty I DAC Dated as of [●], 2023 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1
March 29, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUA Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-388
March 29, 2023	EX-4.5	Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended Exhibit 4.5 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Milestone Pharmaceuticals Inc. (the “Company”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our securit
March 29, 2023	EX-10.18	Consulting Agreement, between the Company and Francis Plat (incorporated herein by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K (File No. 001-38899), filed with the SEC on March 29, 2023). - 1 - Exhibit 10.18 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into this 8th day of November 2022 and will be effective as of January 1, 2023 (the “Effective Date”). BETWEEN: MILESTONE PHARMACEUTICALS INC., a corporation duly incorporated under the Canada Business Corporations Act, having its headoffice at 6210 Ardrey Kell Rd Suite 650, Charlotte, NC 28277
March 29, 2023	EX-99.1	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update - Year-end cash resources, together with $125 million proceeds from March 2023 strategic financing, expected to fund oper Exhibit 99.1 Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update - Year-end cash resources, together with $125 million proceeds from March 2023 strategic financing, expected to fund operations into mid-2025 - NDA submission for etripamil in patients with PSVT expected for 3Q23 Montreal and Charlotte, N.C., Mar. 29, 2023 -
March 29, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 29, 2023	EX-10.19	Non-Employee Director Compensation Policy, as amended. EXHIBIT 10.19 MILESTONE PHARMACEUTICALS INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of Milestone Pharmaceuticals Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Direc
March 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 MILESTONE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 28, 2023	EX-99.1	Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT - Proceeds from strategic financing together with year-end cash resources expected to fund operations into mid- Exhibit 99.1 Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT - Proceeds from strategic financing together with year-end cash resources expected to fund operations into mid-2025 including etripamil NDA submission and launch in PSVT - The combination of etripamil's strong clinical results with this strategic f
March 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 MILESTONE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 27, 2023	EX-4.1	Form of Exchange Warrant (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on March 27, 2023). Exhibit 4.1 UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [●], 20[●]. Milestone Pharmaceuticals Inc. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Number of Shares: [●] (subject to adjustment) Warrant No. PFW2023 - [●] Original Issue Date: [●], 20[●] Milestone Pharmaceuticals Inc., an exempted company incorporated and existing
March 27, 2023	EX-10.1	Exchange Agreement, dated as of March 22, 2023, by and among the Company and certain investors party thereto (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on March 27, 2023). Exhibit 10.1 EXCHANGE AGREEMENT EXCHANGE AGREEMENT (the “Agreement”) is made as of the 22nd day of March 2023, by and among Milestone Pharmaceuticals Inc., a corporation continuing under the Business Corporations Act (Québec) (the “Company”) and each of the investors listed on Schedule A attached hereto (each an “Investor” and collectively, the “Investors”). WHEREAS, the Investors previously acqui
March 10, 2023	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 MILESTONE PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Com
March 7, 2023	EX-99.1	Corporate Overview March 2023 Exhibit 99.1 Corporate Overview March 2023 Forward Looking Statement 2 Milestone Corporate Overview The Presentation contains forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words such as ‘‘aim,’’ ‘‘anticipate,’’ ‘‘assume,’’ ‘‘believe,’’ ‘‘contemplate,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘design,’’ ‘‘due,’’
February 14, 2023	EX-99.1	JOINT FILING AGREEMENT February 14, 2023 EX-99.1 2 d429559dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT February 14, 2023 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule o
February 14, 2023	SC 13G/A	MIST / Milestone Pharmaceuticals Inc / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236584d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement)
February 14, 2023	SC 13G/A	MIST / Milestone Pharmaceuticals Inc / ORBIMED CAPITAL LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ss1758602sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 Milestone Pharmaceuticals, Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Sta
February 14, 2023	SC 13G/A	MIST / Milestone Pharmaceuticals Inc / Boxer Capital, LLC Passive Investment SC 13G/A 1 ff000174212613ga-milesteon.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check
February 14, 2023	SC 13G/A	MIST / Milestone Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statem
February 14, 2023	SC 13G/A	MIST / Milestone Pharmaceuticals Inc / Ikarian Capital, LLC - SC 13G/A Passive Investment SC 13G/A 1 d429559dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate b
January 18, 2023	SC 13G/A	MIST / Milestone Pharmaceuticals Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 MISTSC13GA12023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MILESTONE PHARMACEUTICALS INC. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 59935V107 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropri
December 6, 2022	EX-99.1	Forward Looking Statement2Milestone Commercial Deep-Dive December 6, 2022 ThePresentationcontainsforward-lookingstatementswithinthemeaningofthesafeharborprovisionsofthePrivateSecuritiesLitigationReformActof1995,asamend ed.Wordssuchas‘‘aim,’’‘‘anticip Exhibit 99.1 December 6, 2022Commercial Opportunity Deep Dive for Milestone PharmaceuticalsJoe OlivetoLorenz MullerChief Executive OfficerChief Commercial Officer Forward Looking Statement2Milestone Commercial Deep-Dive December 6, 2022 ThePresentationcontainsforward-lookingstatementswithinthemeaningofthesafeharborprovisionsofthePrivateSecuritiesLitigationReformActof1995,asamend ed.Wordssuchas‘‘ai
December 6, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (
November 10, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 MILESTONE PHARM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation)
November 10, 2022	EX-99.1	Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update - Phase 3 RAPID trial of etripamil in patients with PSVT achieved primary efficacy endpoint; safety and tolerability data from repeat do Exhibit 99.1 Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update - Phase 3 RAPID trial of etripamil in patients with PSVT achieved primary efficacy endpoint; safety and tolerability data from repeat dose administration consistent with prior studies utilizing single-dose administration of etripamil - Analyses from etripamil Phase 3 PSVT
November 10, 2022	EX-10.1	Amended 2019 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38899), filed with the SEC on November 10, 2022). Exhibit 10.1 ? MILESTONE PHARMACEUTICALS INC. ? 2019 EQUITY INCENTIVE PLAN ? ADOPTED BY THE BOARD OF DIRECTORS: APRIL 10, 2019 APPROVED BY THE SHAREHOLDERS: APRIL 29, 2019 IPO DATE: MAY 8, 2019 AMENDED BY THE BOARD OF DIRECTORS: APRIL 19, 2022 APPROVED BY THE SHAREHOLDERS: JULY 5, 2022 ? 1.?????????????GENERAL. ? (a)???????????Successor to and Continuation of Prior Plan. The Plan is intended as th
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc.
October 31, 2022	SC 13G	MIST / Milestone Pharmaceuticals Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MILESTONE PHARMACEUTICALS INC. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 59935V107 (CUSIP Number) OCTOBER 25, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th
October 24, 2022	SC 13D/A	MIST / Milestone Pharmaceuticals Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 59935V107 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to
October 17, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 MILESTONE PHARMA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 MILESTONE PHARMACEUTICALS INC. (Exact name of Registrant as specified in its Charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (
October 17, 2022	EX-99.1	Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia Exhibit 99.1 Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia ? Trial met its primary endpoint, with 64.3% of patients self-administering etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001) ? Consistent safety and tolerability
September 26, 2022	SC 13D/A	MIST / Milestone Pharmaceuticals Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 59935V107 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy t
September 20, 2022	SC 13G	MIST / Milestone Pharmaceuticals Inc / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 59935V107 (CUSIP Number) September 9, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r
August 10, 2022	EX-99.1	Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update - Phase 3 RAPID study reached the target of 180 confirmed PSVT events treated with double-blind study medication required to initiate p Exhibit 99.1 Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update - Phase 3 RAPID study reached the target of 180 confirmed PSVT events treated with double-blind study medication required to initiate primary efficacy analysis; topline data readout for RAPID study remains on track for mid-second half 2022 - Phase 3 PSVT study initiated i
August 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2022 ? OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? Commission File Number: 001-38899 ? ? Milestone Pharmaceuticals Inc.
August 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (C
July 8, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2022 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Qu?bec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Comm
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2022 ? OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? Commission File Number: 001-38899 ? ? Milestone Pharmaceuticals Inc.
May 2, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 tm223588d3def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rul
May 2, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A 1 tm223588d4defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru
April 22, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 PRE 14A 1 tm223588d1pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rul
March 24, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Qu?bec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 24, 2022	EX-99.2	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update - RAPID topline data readout expected in the second half 2022 Exhibit 99.2 Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update - RAPID topline data readout expected in the second half 2022 Montreal and Charlotte, N.C., Mar. 24, 2021 - Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascul
March 24, 2022	EX-99.1	INDEX TO CONSOLIDATED FINANCIAL STATEMENTS ITEM 8. FINANCIAL STATEMENTS Exhibit 99.1 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm (PCAOB ID: 271) 2 Consolidated Balance Sheets 3 Consolidated Statements of Loss 4 Consolidated Statements of Shareholders? Equity 5 Consolidated Statements of Cash Flows 6 Notes to Consolidated Financial Statements 7 1 Report of Independent Registered Public
March 24, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Milestone Pharmaceuticals, Inc.
March 24, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUA Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 24, 2022	EX-4.5	Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended Exhibit 4.5 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Milestone Pharmaceuticals Inc. (the ?Company?) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our securit
March 24, 2022	S-8	As filed with the Securities and Exchange Commission on March 24, 2022 As filed with the Securities and Exchange Commission on March 24, 2022 Registration No.
March 24, 2022	EX-4.10	2021 Inducement Plan, approved by the Board of the Company on November 10, 2021 (incorporated herein by reference to Exhibit 4.10 to the Registrant’s Registration Statement on Form S-8 (File No. 333-263807), filed with the SEC on March 24, 2022). Exhibit 4.10 Milestone Pharmaceuticals Inc. 2021 Inducement Plan Adopted by the Board of Directors: December 10, 2021 1.????????????General. (a)????????????Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the rela
February 16, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Qu?bec 001-38899 Not applicable (state or other jurisdiction of incorporation)
February 16, 2022	EX-10.1	Employment Agreement, dated February 15, 2022 between David Bharucha, M.D., Ph.D. and Milestone Pharmaceuticals USA, Inc. (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on February 16, 2022). Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of February 15, 2022, (the ?Effective Date?) by and between Milestone Pharmaceuticals USA, Inc. (the ?Company?), and David Bharucha (?Executive?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). R E C I T A L S WHEREAS, the Company desires to employ Executive as it
February 16, 2022	EX-99.1	Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer Exhibit 99.1 Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer Montreal and Charlotte, N.C., February 16, 2022 - Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of David Bharucha, M.D., Ph.D., as C
February 14, 2022	SC 13G/A	MIST / Milestone Pharmaceuticals Inc / RTW INVESTMENTS, LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pu
February 14, 2022	SC 13G/A	MIST / Milestone Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi
February 14, 2022	SC 13G/A	MIST / Milestone Pharmaceuticals Inc / Ikarian Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
February 14, 2022	EX-99.1	JOINT FILING AGREEMENT February 14, 2022 EXHIBIT 99.1 JOINT FILING AGREEMENT February 14, 2022 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including a
February 14, 2022	SC 13G/A	MIST / Milestone Pharmaceuticals Inc / Boxer Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule
February 11, 2022	SC 13G/A	MIST / Milestone Pharmaceuticals Inc / ORBIMED CAPITAL LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No.
January 31, 2022	CORRESP	Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 402 Montréal, Québec CA H4M 2X6 CORRESP 1 filename1.htm Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 402 Montréal, Québec CA H4M 2X6 VIA EDGAR January 31, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn:          Christopher Edwards Re:              Milestone Pharmaceuticals Inc. Registration Statement on Form S-3 File No. 33
November 12, 2021	EX-4.7	Milestone Pharmaceuticals Inc. _____________, As Warrant Agent Form of Preferred Share Warrant Agreement Dated As Of __________ Milestone Pharmaceuticals Inc. Form of Preferred Share Warrant Agreement Exhibit 4.7 Milestone Pharmaceuticals Inc. and , As Warrant Agent Form of Preferred Share Warrant Agreement Dated As Of Milestone Pharmaceuticals Inc. Form of Preferred Share Warrant Agreement This Preferred Share Warrant Agreement (this ?Agreement?), dated as of [?], between Milestone Pharmaceuticals Inc., a corporation existing under the laws of the province of Qu?bec (the ?Company?), and [?], a
November 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Qu?bec 001-38899 Not applicable (state or other jurisdiction of incorporation)
November 12, 2021	EX-4.8	Milestone Pharmaceuticals Inc. _____________, As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of __________ Milestone Pharmaceuticals Inc. Form of Debt Securities Warrant Agreement Exhibit 4.8 Milestone Pharmaceuticals Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Milestone Pharmaceuticals Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this ?Agreement?), dated as of [?], between Milestone Pharmaceuticals Inc., a corporation organized under the laws of the province of Qu?bec (the ?Company?), and [?],
November 12, 2021	S-3	As filed with the Securities and Exchange Commission on November 12, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 12, 2021 Registration No.
November 12, 2021	EX-4.6	Milestone Pharmaceuticals Inc. _____________, As Warrant Agent Form of Common Share Warrant Agreement Dated As Of __________ Milestone Pharmaceuticals Inc. Form of Common Share Warrant Agreement Exhibit 4.6 Milestone Pharmaceuticals Inc. and , As Warrant Agent Form of Common Share Warrant Agreement Dated As Of Milestone Pharmaceuticals Inc. Form of Common Share Warrant Agreement This Common Share Warrant Agreement (this ?Agreement?), dated as of [?], between MILESTONE PHARMACEUTICALS INC., a corporation existing under the laws of the province of Qu?bec (the ?Company?), and [?], a [corpora
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2021 ? OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? Commission File Number: 001-38899 ? ? Milestone Pharmaceuticals Inc.
November 12, 2021	EX-99.2	Joseph Oliveto President & CEO Corporate Overview November 2021 Disclaimers The Presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Wor Exhibit 99.2 Joseph Oliveto President & CEO Corporate Overview November 2021 Disclaimers The Presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words such as ??aim,?? ??anticipate,?? ??assume,?? ??believe,?? ??contemplate,?? ??continue,?? ??could,?? ??design,?? ??due,?? ??estimate,??
November 12, 2021	EX-4.4	Milestone Pharmaceuticals Inc., [TRUSTEE], Trustee Dated as of [·], 20__ Debt Securities Table Of Contents Exhibit 4.4 Milestone Pharmaceuticals Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificat
November 12, 2021	EX-99.1	Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update Exhibit 99.1 Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update Montreal and Charlotte, N.C., Nov. 12, 2021 - Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended Se
November 4, 2021	CORRESP	Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 402 Montréal, Québec CA H4M 2X6 CORRESP 1 filename1.htm Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 402 Montréal, Québec CA H4M 2X6 VIA EDGAR November 4, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christopher Edwards Re: Milestone Pharmaceuticals Inc. Registration Statement on Form S-3, as amended File No. 333-257404 A
October 28, 2021	S-3/A	As filed with the Securities and Exchange Commission on October 28, 2021 S-3/A 1 tm2130817-1s3a.htm S-3/A TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 28, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Milestone Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Québec
October 5, 2021	CORRESP	MILESTONE PHARMACEUTICALS INC. 1111 Dr. Frederik-Philips Boulevard, Suite 402 Montréal, Québec CA H4M 2X6 CORRESP 1 filename1.htm MILESTONE PHARMACEUTICALS INC. 1111 Dr. Frederik-Philips Boulevard, Suite 402 Montréal, Québec CA H4M 2X6 October 5, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christopher Edwards Re: Withdrawal of Acceleration Request of Milestone Pharmaceuticals Inc. Registration Statement on Form
October 1, 2021	CORRESP	Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 402 Montréal, Québec CA H4M 2X6 Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 402 Montréal, Québec CA H4M 2X6 VIA EDGAR October 1, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christopher Edwards Re: Milestone Pharmaceuticals Inc. Registration Statement on Form S-3 Filed June 25, 2021 File No. 333-257404 Acceleration Reque
August 11, 2021	EX-10.1	License and Collaboration Agreement by and among the Company and Ji Xing Pharmaceuticals, Limited, dated May 15, 2021 (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38899), filed with the SEC on August 11, 2021. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
August 11, 2021	EX-4.1	Form of Pre-Funded Warrants to Purchase Common Shares Exhibit 4.1 ? ? NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG
August 11, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2021 ? OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? Commission File Number: 001-38899 ? ? Milestone Pharmaceuticals Inc.
June 25, 2021	S-3	Power of Attorney (included on signature page). TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 25, 2021 Registration No.
June 25, 2021	EX-10.2	Form of Pre-Funded Warrant to Purchase Common Shares. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
June 25, 2021	EX-10.1	Securities Purchase Agreement dated May 21, 2021. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of May 21, 2021 (the ?Effective Date?) by and among Milestone Pharmaceuticals Inc., a corporation continuing under the Business Corporations Act (Qu?bec) (the ?Company?) and each of those persons listed as a Purchaser on the Schedule of Purchasers attached as Schedule I here
June 21, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Qu?bec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Com
June 2, 2021	EX-99.1	Joseph Oliveto President & CEO Corporate Overview June 2021 Exhibit 99.1 Joseph Oliveto President & CEO Corporate Overview June 2021 Disclaimers The Presentation contains forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 , as amended . Words such as ??aim,?? ??anticipate,?? ??assume,?? ??believe,?? ??contemplate,?? ??continue,?? ??could,?? ??design,?? ??due,?? ??estimate,??
June 2, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Qu?bec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Comm
May 17, 2021	EX-99.1	Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China - Ji Xing Pharmaceuticals to develop and commercialize etripamil for patients with PSVT in G Exhibit 99.1 Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China - Ji Xing Pharmaceuticals to develop and commercialize etripamil for patients with PSVT in Greater China - - Milestone to receive a $15 million upfront cash payment and a $5 million equity investment by RTW Investments, LP - Mont
May 17, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2021 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Qu?bec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Comm
May 17, 2021	EX-10.1	The Non-employee Director Compensation Policy, as amended. Exhibit 10.1 Milestone Pharmaceuticals Inc. ? Amended and Restated Non-Employee Director Compensation Policy ? Each member of the Board of Directors (the ?Board?) of Milestone Pharmaceuticals Inc. (the ?Company?) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Di
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2021 ? OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? Commission File Number: 001-38899 ? ? Milestone Pharmaceuticals Inc.
April 30, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 30, 2021	DEF 14A	our definitive Proxy Statement on Schedule 14A, filed with the SEC on April 30, 2021, to the extent the information therein is filed and not furnished. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
March 30, 2021	EX-99.1	Milestone Pharmaceuticals Inc. Consolidated Balance Sheets (in thousands of US dollars, except share data) Exhibit 99.1 ITEM 8. FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Milestone Pharmaceuticals Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Milestone Pharmaceuticals Inc. and its subsidiary (together, the Company) as of December 31, 2020 and 2019, and the related c
March 30, 2021	EX-99.2	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update Exhibit 99.2 Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update Montreal and Charlotte, N.C., March 29, 2021 - Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth
March 30, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Qu?bec 001-38899 Not applicable (state or other jurisdiction of incorporation) (Co
March 29, 2021	10-K	Annual Report - 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 29, 2021	EX-4.3	Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended Exhibit 4.3 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Milestone Pharmaceuticals Inc. (the ?Company?) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our securit
March 29, 2021	S-8	March 29, 2021 (File No. 333- 254838) As filed with the Securities and Exchange Commission on March 29, 2021 Registration No.
February 16, 2021	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the common shares of Milestone Pharmaceuticals Inc., no par value, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as am
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 59935V107 (CUSIP Number) 31 DECEMBER 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securitie SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) (CUSIP Number UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 12, 2021	EX-1	Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No.
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MILESTONE PHARMACEUTICALS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
February 12, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SC 13G 1 ss192041sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Milestone Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appr
January 21, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Milestone Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 59935V107 (CUSIP Number) December 31, 2020 Date
January 11, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) (CUSIP Numbe SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Milestone Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 59935V107 (CUSIP Number) August 3, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
January 11, 2021	EX-99.1	JOINT FILING AGREEMENT January 11, 2021 EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT January 11, 2021 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (incl
December 16, 2020	CORRESP	- Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 402 Montréal, Québec CA H4M 2X6 VIA EDGAR December 16, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Paul Fischer Re: Milestone Pharmaceuticals Inc. Registration Statement on Form S-3 Filed August 20, 2020 File No. 333-248198 Acceleration Request
November 13, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc.
November 13, 2020	EX-10.3	The Non-employee Director Compensation Policy, as amended. Exhibit 10.3 MILESTONE PHARMACEUTICALS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of Milestone Pharmaceuticals Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Polic
October 26, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2020 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation) (
October 26, 2020	EX-4.1	Form of Pre-Funded Warrant Exhibit 4.1 Milestone Pharmaceuticals Inc. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Number of Shares: [-] (subject to adjustment) Warrant No. PFW – 00[-] Original Issue Date: October [-], 2020 Milestone Pharmaceuticals Inc., an exempted company incorporated and existing under the laws of the Province of Québec, Canada (the “Company”), hereby certifies that, for good and valuable consid
October 26, 2020	EX-99.1	Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded Warrants Exhibit 99.1 Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded Warrants MONTREAL and CHARLOTTE, N.C., Oct. 23, 2020 /PRNewswire/ - Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical- stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today
October 26, 2020	EX-1.1	Underwriting Agreement, dated October 22, 2020, by and among the Company, Jefferies LLC and Piper Sandler & Co. Exhibit 1.1 Execution Version 3,810,097 Common Shares and Pre-Funded Warrants to Purchase 4,761,903 Common Shares Milestone Pharmaceuticals Inc. UNDERWRITING AGREEMENT October 22, 2020 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 and c/o PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minnea
October 26, 2020	424B5	3,810,097 Common Shares Pre-Funded Warrants to Purchase 4,761,903 Common Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-239318 PROSPECTUS SUPPLEMENT (To Prospectus dated July 6, 2020) 3,810,097 Common Shares Pre-Funded Warrants to Purchase 4,761,903 Common Shares We are offering 3,810,097 common shares pursuant to this prospectus supplement. We are also offering to certain investors the opportunity to purchase, in lieu of common shares, warra
October 23, 2020	10-K/A	Annual Report - 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-
October 22, 2020	424B5	Common Shares Pre-Funded Warrants to Purchase Common Shares TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.
October 22, 2020	S-3MEF	- FORM S-3MEF As filed with the Securities and Exchange Commission on October 22, 2020 Registration No.
September 22, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Québec 001-38899 Not applicable (state or other jurisdiction of incorporation)
September 22, 2020	EX-99.1	Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments Exhibit 99.1 Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments Montreal and Charlotte, N.C., September 22, 2020 - Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Lisa Giles and Robert Wills to its Board of Directors,
August 20, 2020	S-3	Power of Attorney (included on signature page). TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 20, 2020 Registration No.
August 12, 2020	10-Q	August 12, 2020 Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2020 ? OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? Commission File Number: 001-38899 ? ? Milestone Pharmaceuticals Inc.

MIST / Milestone Pharmaceuticals Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)